Literature DB >> 3762266

Pharmacokinetics of droxicam in rat and dog.

A Esteve, L Martínez, R Roser, R Sagarra.   

Abstract

A study was made of the oral absorption of droxicam in the rat. Five minutes after administration of 1 mg/kg droxicam, only piroxicam levels (its active metabolite) were detected at the portal vein and caudal vena cava. The transformation of droxicam into piroxicam takes place in the gastrointestional tract. A pharmacokinetic test to compare the plasma levels of piroxicam obtained in rat and dog was then made after oral administration of droxicam and piroxicam. In both animal species the oral absorption of droxicam was not dose-related. However, droxicam given at therapeutic doses (0.2-0.3 mg/kg) was bioequivalent to piroxicam. The elimination half-life of piroxicam after oral administration of droxicam and piroxicam was 8 +/- 2 h in the male rat, 27 +/- 12 h in the female rat and 38 +/- 18 h in the male dog, whilst the half-life of oral absorption of piroxicam did not vary from one animal species to another. In the case of droxicam, however, this value was higher than that after oral administration of piroxicam, as a consequence of the process of transformation of droxicam into piroxicam. It is concluded that droxicam is a prodrug of piroxicam with a slower rate of absorption, but with the same bioavailability within the range of therapeutic doses.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3762266

Source DB:  PubMed          Journal:  Methods Find Exp Clin Pharmacol        ISSN: 0379-0355


  4 in total

1.  Single and multiple dose pharmacokinetics of a new NSAID (droxicam) in healthy volunteers.

Authors:  L Martinez; J Sanchez; R Roser; J Garcia-Barbal; R Sagarra; A Bartlett
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1989 Oct-Dec       Impact factor: 2.441

2.  Ampiroxicam, an anti-inflammatory agent which is a prodrug of piroxicam.

Authors:  T J Carty; A Marfat; P F Moore; F C Falkner; T M Twomey; A Weissman
Journal:  Agents Actions       Date:  1993-07

Review 3.  Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents.

Authors:  K T Olkkola; A V Brunetto; M J Mattila
Journal:  Clin Pharmacokinet       Date:  1994-02       Impact factor: 6.447

4.  Cross-over study of the bioavailability of a new NSAID (droxicam) versus piroxicam in healthy volunteers following single and multiple dose administration.

Authors:  A Bartlett; A Costa; L Martinez; R Roser; R Sagarra; J Sanchez
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1992 Jul-Sep       Impact factor: 2.441

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.